Li Yue-Mei, Liu Qiang, Li Xiang-Yang
Department of Acupuncture and Moxibustion, First Hospital Affiliated to Guangzhou University of CM, Guangzhou 510405, China.
Zhongguo Zhen Jiu. 2012 May;32(5):459-63.
To observe the therapeutic effect and mechanism of new percutaneous absorption herbal patch for asthma of paracmasis, and to optimize the form of the patch.
One hundred and twenty cases of paracmasis asthma were randomly divided into medicine patch group, medicinal vesiculation group and western medication group with 40 cases for each. The new percutaneous absorption herbal patch was applied on medicine patch group. Traditional medicinal herbs cake of the hospital were applied on medicinal vesiculation group. Feishu (BL 13), Fengmen (BL 12) and Dazhui (GV 14) were adopted for both groups. Each patch was applied for 6 hours and once every other day. Accuhaler was applied on the western medicine group with 2 inhalations a time and twice a day. Clinical symptom scores, number of attacks and asymtomatic days were observed right before, after and half a year after the treatment. Meanwhile, the expression level of IgE, IL-4, GATA-3 mRNA and T-bet mRNA were observed and compared before and after the treatment.
Clinical symptom scores of all the 3 groups were improved (all P < 0.01). The differences of the total effective rate, number of attacks and asymtomatic days of all the 3 groups are without statistical significance (all P > 0.05). However, the long-term therapeutic effect in half a year after the treatment showed that the total effective rate of the medicine patch group was 80.0% (32/40), and the medicinal vesiculation group was 70.0% (28/40). Both of the them were obviously higher than 47.5% (19/40) of the western medicine group (P < 0.01, P < 0.05). And the medicine patch group surpassed the other 2 groups in controlling the number of attacks and increasing the asymtomatic days (P < 0.05, P < 0.01). The level of IgE and IL-4 of all the 3 groups decreased sharply after the treatment (P < 0.05, P < 0.01). And there was no statistic significance in differences among groups (all P > 0.05). The level of GATA-3 mRNA was obviously decreased, while the level of T-bet mRNA was obviouly increased in the medicine patch and medicinal vesiculation groups (P < 0.05, P < 0.01). And the medicine patch group had obvious superiority on increasing the level of T-bet mRNA when compared with the medicinal vesiculation and western medicine groups (P < 0.01, P < 0.05).
It is concluded that the new percutaneous absorption herbal patch has exact effect on asthma. The treatment may reverse the imbalance condition of Th1/Th2 through regulation on cell factor and its specific transcription factors.
观察新型经皮吸收中药贴剂对缓解期哮喘的治疗作用及机制，并优化贴剂剂型。
将120例缓解期哮喘患者随机分为药贴组、药物发泡组和西药组，每组40例。药贴组应用新型经皮吸收中药贴剂，药物发泡组应用本院传统中药饼，两组均选取肺俞（BL 13）、风门（BL 12）、大椎（GV 14）。每贴敷贴6小时，隔日1次。西药组应用舒利迭，每次2吸，每日2次。观察治疗前、治疗后及治疗半年后临床症状评分、发作次数和无症状天数。同时，观察并比较治疗前后各组IgE、IL - 4、GATA - 3 mRNA和T - bet mRNA的表达水平。
3组临床症状评分均改善（均P < 0.01）。3组总有效率、发作次数和无症状天数比较，差异均无统计学意义（均P > 0.05）。但治疗半年后的远期疗效显示，药贴组总有效率为80.0%（32/40），药物发泡组为70.0%（28/40），均明显高于西药组的47.5%（19/40）（P < 0.01，P < 0.05）。且药贴组在控制发作次数和增加无症状天数方面优于其他两组（P < 0.05，P < 0.01）。3组治疗后IgE和IL - 4水平均显著降低（P < 0.05，P < 0.01），组间差异无统计学意义（均P > 0.05）。药贴组和药物发泡组GATA - 3 mRNA水平明显降低，T - bet mRNA水平明显升高（P < 0.05，P < 0.01）。与药物发泡组和西药组比较，药贴组在提高T - bet mRNA水平方面具有明显优势（P < 0.01，P < 0.05）。
新型经皮吸收中药贴剂治疗哮喘疗效确切，其治疗作用可能是通过调节细胞因子及其特异性转录因子，逆转Th1/Th2失衡状态。
